bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract For CyPath Lung Test
Portfolio Pulse from Benzinga Newsdesk
bioAffinity Technologies has secured a U.S. Federal Supply Schedule contract for its CyPath Lung test, a noninvasive diagnostic for early-stage lung cancer. This will provide U.S. Veterans and other federal health services patients with access to the test.
October 09, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
bioAffinity Technologies' CyPath Lung test is now available through the U.S. Federal Supply Schedule, potentially increasing its market reach and revenue by providing access to Veterans and federal health services.
The inclusion of CyPath Lung in the U.S. Federal Supply Schedule allows bioAffinity Technologies to tap into a large market of Veterans and federal health services, potentially increasing sales and revenue. This strategic move is likely to positively impact BIAF's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90